In Segment C, members will acquire ABBV-744 and oral navitoclax. In Phase D, participants will receive ABBV-744 and ruxolitinib. Members will get treatment till condition progression or perhaps the individuals are not able to tolerate the study drugs. and then market H3K27Ac at this region. Chromatin hyperacetylation could boost the https://nealea443sfp7.rimmablog.com/profile